The progression of some inflammatory diseases, including atherosclerosis [29], rheumatoid arthritis [30], and NAFLD [31,32], is associated with the increased expression of CCL3 and its receptors. Here, CCL3 is linked to metabolic dysfunction-associated steatotic liver disease.